Department of Microbiology, National Autonomous University of Honduras, Tegucigalpa, Honduras.
J Med Virol. 2012 Oct;84(10):1514-21. doi: 10.1002/jmv.23381.
Transmitted drug resistance has important implications for the successful use and management of therapy among persons infected with HIV. We estimated the prevalence of transmitted drug resistance in 145 samples from female sex workers (n = 47) and men who have sex with men (n = 98) in El Salvador. Samples were collected during March to September 2008, using a respondent driven sampling. The HIV-1 pol gene was sequenced to identify drug resistance mutations and transmitted drug resistance was scored as recommended by World Health Organization. Specimens were classified as recent or established infections using the Immunoglobulin G-Capture BED-Enzyme Immunoassay. The overall prevalence of transmitted drug resistance was 9.4% (95% CI: 4.7-16.1%), and was 5.9% for non-nucleoside reverse transcriptase inhibitors, 4.2% for nucleoside reverse transcriptase inhibitors, and 0.8% for protease inhibitors. Transmitted drug resistance prevalence was 10.3% (95% CI: 2.8-24.2%) among female sex workers, and 9.0% (95% CI: 3.6-17.6%) among men who have sex with men. Nineteen patients were classified as having recent infection (16.2%, 95% CI: 10.1-24.2%), while 98 patients (83.8%, 95% CI: 75.8-89.9%) were classified as having established infections. Transmitted drug resistance among recent and established infections was similar at 10.5% and 9.2%, respectively. This study shows that the prevalence of transmitted drug resistance is moderate among female sex workers and men who have sex with men in El Salvador. These results highlight the importance of transmitted drug resistance surveillance in a representative sample of recently infected patients following the World Health Organization guidelines.
传播性耐药对感染 HIV 的人群的治疗成功使用和管理具有重要意义。我们估计了 145 份来自萨尔瓦多女性性工作者(n = 47)和男男性行为者(n = 98)样本中的传播性耐药流行率。这些样本是在 2008 年 3 月至 9 月期间使用应答驱动抽样法采集的。对 HIV-1 pol 基因进行测序,以鉴定耐药突变,并按照世界卫生组织的建议对传播性耐药进行评分。使用 IgG 捕获 BED-酶免疫测定法将标本分类为近期或已建立的感染。总的传播性耐药流行率为 9.4%(95%CI:4.7-16.1%),非核苷类逆转录酶抑制剂耐药率为 5.9%,核苷类逆转录酶抑制剂耐药率为 4.2%,蛋白酶抑制剂耐药率为 0.8%。女性性工作者的传播性耐药流行率为 10.3%(95%CI:2.8-24.2%),男男性行为者的传播性耐药流行率为 9.0%(95%CI:3.6-17.6%)。19 名患者被归类为近期感染(16.2%,95%CI:10.1-24.2%),而 98 名患者(83.8%,95%CI:75.8-89.9%)被归类为已建立的感染。近期和已建立的感染中的传播性耐药率分别为 10.5%和 9.2%,两者相似。这项研究表明,萨尔瓦多的女性性工作者和男男性行为者中传播性耐药的流行率中等。这些结果强调了按照世界卫生组织的指导方针,对近期感染患者进行代表性样本的传播性耐药监测的重要性。